<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02004067</url>
  </required_header>
  <id_info>
    <org_study_id>17821013.0.0000.5505</org_study_id>
    <nct_id>NCT02004067</nct_id>
  </id_info>
  <brief_title>Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease</brief_title>
  <official_title>Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study the investigators aim to determine the efficacy of an immunomodulating&#xD;
      topical medication, compared with a topical lubricant, on the treatment of dry eye disease&#xD;
      (DED) due to primary or secondary Sjögren's syndrome (aqueous deficient DED) and evaporative&#xD;
      DED.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that&#xD;
      results in symptoms of discomfort, visual disturbance, and tear film instability with&#xD;
      potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear&#xD;
      film and inflammation of the ocular surface. DED prevalence is estimated around 15 -35% of&#xD;
      the population over 50 years old. There is a wide variety of topic medications for the&#xD;
      treatment of DED, though few aim the re-establishment of tear osmolarity equilibrium and&#xD;
      reduction of damages to the ocular surface. The treatment of DED can include a medical&#xD;
      treatment, such as tear substitution, tear preservation, production stimulation,&#xD;
      anti-inflammatory; it can also include surgical treatment, as tarsorrhaphy and salivary gland&#xD;
      transplant. Considering tear substitutes and anti-inflammatory topical treatments, the&#xD;
      purpose of our study is to determine efficacy of an immunomodulating topical medication&#xD;
      containing 0.05% cyclosporine A (CsA), compared to a topical lubricant (vitamin A, Refresh&#xD;
      Endura®), on the treatment of dry eye disease (DED) due to primary or secondary Sjögren's&#xD;
      syndrome (aqueous deficient DED) and evaporative DED.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular surface inflammation</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Sjogren Syndrome</condition>
  <condition>Secondary Sjogren Syndrome</condition>
  <condition>Aqueous Deficient Dry Eye Disease</condition>
  <condition>Evaporative Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Refresh Endura</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Restasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
    <description>Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.</description>
    <arm_group_label>Restasis</arm_group_label>
    <other_name>Cyclosporine 0.05%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Endura</intervention_name>
    <description>Refresh Endura is a topical lubricant produced by Allergan, Inc.</description>
    <arm_group_label>Refresh Endura</arm_group_label>
    <other_name>Castor oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed for mild to moderate Aqueous Deficient DED (ADDED), defined as&#xD;
             Schirmer 1 &lt; 10mm;&#xD;
&#xD;
          -  Patients diagnosed for mild to moderate Evaporative DED (EDED), defined as normal&#xD;
             Schirmer 1 and BUT &lt; 5 seconds;&#xD;
&#xD;
          -  Patients submitted to refractive surgery,&#xD;
&#xD;
          -  Patients capable of understanding instructions, signing the term of consent and&#xD;
             available to attend all exam visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with punctual occlusion,&#xD;
&#xD;
          -  active ocular infection or inflammatory disease,&#xD;
&#xD;
          -  history of herpetic keratitis,&#xD;
&#xD;
          -  contact lens use during trial period,&#xD;
&#xD;
          -  patients with glaucoma,&#xD;
&#xD;
          -  any eyelid globe malposition abnormality.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossen M Hazarbassanov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departamento de Oftalmologia da Escola Paulista de Medicina - UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023 062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>September 20, 2020</last_update_submitted>
  <last_update_submitted_qc>September 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Rossen Mihaylov Hazarbassanov, MD, PhD</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Evaporative</keyword>
  <keyword>Aqueous deficient</keyword>
  <keyword>Dry eye disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Castor Oil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

